Sarepta Receives FDA Platform Technology Designation for Viral Vector in SRP-9003
|
Market Closed –
|
5-day change | 1st Jan Change | ||
|
43.01 USD |
+9.69% |
|
+14.39% | -64.63% |
Published on 06/04/2025 at 10:28
This article is reserved for members Unlock the article: REGISTER NOW!
© MT Newswires – 2025
|
Sarepta Therapeutics Shares Rise After Upgrade From Scotiabank |
Jun. 06 |
MT |
|
Wall Street’s Balancing Act |
Jun. 06 |
 |
|
Scotiabank Upgrades Sarepta Therapeutics to Sector Outperform From Sector Perform, $80 Price Target |
Jun. 06 |
MT |
|
Analyst recommendations: Crowdstrike Holdings, Broadcom, Lululemon, Zscaler… |
Jun. 06 |
|
|
Sarepta Receives FDA Platform Technology Designation for Viral Vector in SRP-9003 |
Jun. 04 |
MT |
|
FDA Grants Platform Tech Designation To Viral Vector In Sarepta’s SRP-9003 For LGMD Type 2E/R4 |
Jun. 04 |
RE |
|
U.S. FDA Grants Platform Technology Designation to the Viral Vector Used in SRP-9003, Sarepta’s Investigational Gene Therapy for the Treatment of Limb Girdle Muscular Dystrophy Type 2E/R4 |
Jun. 04 |
CI |
|
FDA halts Rocket Pharma’s gene therapy trial as patient dies |
May. 27 |
RE |
|
Sarepta Therapeutics, Inc. Provides Update on UK Dosing in ENVISION Study of Eletidys for the Treatment of Duchenne Muscular Dystrophy |
May. 21 |
CI |
|
Sarepta Therapeutics Says Dosing to Continue in UK Trial of Duchenne Muscular Dystrophy Treatment |
May. 21 |
MT |
|
Sarepta Provides Update on UK Dosing in ENVISION Study of ELEVIDYS for the treatment of Duchenne Muscular Dystrophy |
May. 21 |
RE |
|
The Fragile Confidence Act |
May. 20 |
|
|
Analyst recommendations; Applovin, HP, Metlife, Micron, Pure Storage…. |
May. 20 |
|
|
Sarepta Therapeutics, Inc. Presents Data At the American Society of Gene & Cell Therapy Conference, Including Statistically Significant Functional Outcomes for 8- and 9-Year-Old Patients in New Data Analysis of EMBARK Part 2 |
May. 16 |
CI |
|
Sarepta Therapeutics, Inc. Shares New Protein Expression and Safety Results from Endeavor in Participants 2 Years Old At Time of Treatment |
May. 16 |
CI |
|
Sarepta Reports New Elevidys Data from Two Separate Studies in Duchenne Muscular Dystrophy |
May. 16 |
MT |
|
When the Numbers Don’t Add Up |
May. 15 |
|
|
Analyst recommendations: Nvidia, On Holding, Duolingo, Target, UnitedHealth… |
May. 15 |
|
|
Sarepta Therapeutics, Inc. Presents at BofA Securities 2025 Healthcare Conference, May-14-2025 08:40 AM |
May. 14 |
|
|
Sarepta Therapeutics Says Duchenne Muscular Dystrophy Treatment Gets Approval in Japan |
May. 13 |
MT |
|
Sarepta Therapeutics, Inc. Announces Approval in Japan of ELEVIDYS, A Gene Therapy to Treat Duchenne Muscular Dystrophy |
May. 13 |
CI |
|
Eighty Percent and Falling |
May. 09 |
|
|
Analyst recommendations: Airbnb, AMD, Fortinet, Uber, Estee Lauder… |
May. 09 |
|
|
UBS Cuts Price Target on Sarepta Therapeutics to $85 From $188, Keeps Buy Rating |
May. 08 |
MT |
|
About Doves and Deals |
May. 07 |
|
SRPT: Dynamic Chart
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. It has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. It has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes approximately 40 programs at various stages of discovery, pre-clinical and clinical development.
More about the company
Buy
Average target price
89.96USD
Spread / Average Target
+109.16%
Consensus
Quarterly revenue – Rate of surprise
Select your edition
All financial news and data tailored to specific country editions
link
